Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedifosfamide
Educational only, not medical advice. OncoForge makes no claim that Ifosfamide treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
This randomized phase III study compared paclitaxel plus carboplatin with paclitaxel plus ifosfamide in adults with uterine or ovarian carcinosarcoma. In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to the ifosfamide regimen and had longer median overall survival and progression-free survival. Toxicities were broadly similar, although some side effects differed between the two groups.
Reported effects: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 · HR 0.87 [0.7–1.075], p P < .01 for noninferiority, P > .1 for superiority, n=449 · +4 more
Studied with: carboplatin, ifosfamide.
Key findings
In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to paclitaxel plus ifosfamide for overall survival.
Median overall survival was 37 versus 29 months in uterine carcinosarcoma.
Median progression-free survival was 16 versus 12 months in uterine carcinosarcoma.
Toxicities were similar overall, with more hematologic toxicity in the paclitaxel-carboplatin arm and more confusion and genitourinary hemorrhage in the paclitaxel-ifosfamide arm.
In ovarian carcinosarcoma, paclitaxel plus carboplatin had numerically longer survival outcomes, but the differences were not statistically significant.
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
This study evaluates chemotherapy regimens in carcinosarcoma, a cancer setting, with direct survival and toxicity outcomes.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Ifosfamide's evidence base, and anything that's been retracted.
Cancers where Ifosfamide reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies
Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies
These are doses as studied or reported, never a recommendation. The right amount of Ifosfamide depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
0 ongoing · 0 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.